Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 7/20 | 0.77 |
| ▸ | KDR | P35968 | 3/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 6/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | EIF4E | P06730 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5229192 | 0.90 | TGFBR1 (0.62) | TGFBR1MAPK14HDAC4HDAC6CDK2 | |
| SCHEMBL5199606 | 0.90 | TGFBR1 (0.82) | TGFBR1KDRMAPK14GABRA5HDAC4 | |
| SCHEMBL5197802 | 0.89 | TGFBR1 (0.62) | TGFBR1KDRMAPK1 | |
| SCHEMBL6222961 | 0.87 | TGFBR1 (1.00) | TGFBR1KDRMAPK14 | |
| SCHEMBL5197598 | 0.86 | TGFBR1 (0.57) | TGFBR1MAPK14 | |
| SCHEMBL5200669 | 0.83 | TGFBR1 (0.51) | TGFBR1KDRMAPK14 | |
| SCHEMBL5222935 | 0.81 | TGFBR1 (0.51) | TGFBR1MAPK14HDAC6 | |
| SCHEMBL5228813 | 0.80 | TGFBR1 (0.50) | TGFBR1 | |
| SCHEMBL5199443 | 0.80 | TGFBR1 (0.50) | TGFBR1 | |
| SCHEMBL5198595 | 0.80 | TGFBR1 (0.48) | TGFBR1MAPK14MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275968-A1 | Substituted Biphenyl Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-11-29 | — | — | US | claimed |
| EP-1798229-A1 | SUBSTITUTED BIPHENYL DERIVATIVE | Sankyo Company, Limited (JP) | 2007-06-20 | — | — | EP | claimed |
| US-20070275968-A1 | Substituted Biphenyl Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1798229-A1 | SUBSTITUTED BIPHENYL DERIVATIVE | Sankyo Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275968-A1 | Substituted Biphenyl Derivative | COL2A1, COL1A1, FGFR3 | TGFBR1 40/4885KDR 1163/4885MAPK14 2998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.